1. Home
  2. HAWK vs COLL Comparison

HAWK vs COLL Comparison

Compare HAWK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HawkEye 360 Inc. Common Stock

HAWK

HawkEye 360 Inc. Common Stock

HOLD

Current Price

$12.33

Market Cap

1.2B

Sector

Technology

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$22.99

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HAWK
COLL
Founded
2015
2002
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2026
2015

Fundamental Metrics

Financial Performance
Metric
HAWK
COLL
Price
$12.33
$22.99
Analyst Decision
Strong Buy
Buy
Analyst Count
11
8
Target Price
$29.10
★ $49.00
AVG Volume (30 Days)
★ 1.3M
649.6K
Earning Date
11-12-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $780,567,000.00
Revenue This Year
$84.65
$6.73
Revenue Next Year
$25.27
$1.37
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 23.62
52 Week Low
$11.41
$21.43
52 Week High
$25.71
$50.79

Technical Indicators

Market Signals
Indicator
HAWK
COLL
Relative Strength Index (RSI) 30.59 49.28
Support Level N/A $21.51
Resistance Level $17.42 $23.87
Average True Range (ATR) 0.64 0.75
MACD 0.02 0.28
Stochastic Oscillator 30.89 58.86

Price Performance

Historical Comparison
HAWK
COLL

About HAWK HawkEye 360 Inc. Common Stock

Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: